Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Bemused As NICE Says No Again To Migraine Drug Aimovig

Executive Summary

The Swiss major is evaluating whether or not there is a case to appeal after the cost watchdog said it is “very uncertain" whether the CGRP inhibitor is more clinically effective for migraine than Botox.

You may also be interested in...



Scottish HTA Body OKs Novartis’ Aimovig For Migraine And Eisai’s Lenvima For Cancer

Scotland’s health technology appraisal body has OKd Novartis’s Aimovig for migraines. England’s NICE has postponed a meeting on the drug after a large number of comments were received following the institute’s initial knockback.

Novartis To Ape Aimovig's US Market Strategy In The EU As CHMP Gives Market Go-Ahead

Swiftly following its first approval in the US, Amgen/Novartis' Aimovig has just been given a CHMP go-ahead in the EU positioning it to be the first CGRP targeting agent on the market there. Launch tactics look set to mirror those in the US.

Poland’s Ryvu Bets Big On Blood Cancer Candidate

Ryvu has only about $7m in cash and equivalents but believes that a mixture of venture debt, milestones from partners and tapping the equity capital markets will provide the funds to advance RVU120 for acute myeloid leukemia and myelodysplastic syndrome.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel